| [1] |
韩承祚, 卫强, 徐骁. 移植肿瘤学开创肝移植治疗肝癌新时代[J]. 临床肝胆病杂志, 2021, 37(2):253-256.
|
| [2] |
Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med, 1996, 334(11):693-699.
|
| [3] |
Mazzaferro V, Citterio D, Bhoori S, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial[J]. Lancet Oncol, 2020, 21(7):947-956.
|
| [4] |
Zhan QF, Ling SB, Deng YN, et al. Hangzhou criteria as downstaging criteria in hepatocellular carcinoma before liver transplantation: a multicenter study from China[J]. Hepatobiliary Pancreat Dis Int, 2020, 19(4):349-357.
|
| [5] |
Jiang G, Ling S, Zhan Q, et al. Downstaging treatment for patients with hepatocelluar carcinoma before transplantation[J]. Transplant Rev, 2021, 35(2):100606.
|
| [6] |
Chapman WC, Majella Doyle MB, Stuart JE, et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation[J]. Ann Surg, 2008, 248(4):617-625.
|
| [7] |
Vogel A, Martinelli E, ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines[J]. Ann Oncol, 2021, 32(6):801-805.
|
| [8] |
El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088):2492-2502.
|
| [9] |
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20):1894-1905.
|
| [10] |
Liu H, Xu Y, Xiang J, et al. Targeting alpha-fetoprotein (AFP)-MHC complex with CAR T-cell therapy for liver cancer[J]. Clin Cancer Res, 2017, 23(2):478-488.
|
| [11] |
Nordness MF, Hamel S, Godfrey CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient?[J]. Am J Transplant, 2020, 20(3):879-883.
|
| [12] |
Schwacha-Eipper B, Minciuna I, Banz V, et al. Immunotherapy asa downstaging therapy for liver transplantation[J]. Hepatology, 2020, 72(4):1488-1490.
|
| [13] |
Tabrizian P, Florman SS, Schwartz ME. PD-1 inhibitor as bridge therapy to liver transplantation?[J]. Am J Transplant, 2021, 21(5): 1979-1980.
|
| [14] |
Chao J, Zhu Q, Chen D, et al. Case report: transarterial chemoembolization in combination with tislelizumab downstages unresectable hepatocellular carcinoma followed by radical salvage resection[J]. Front Oncol, 2021(11):667555.
|
| [15] |
Chen GH, Wang GB, Huang F, et al. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period[J]. Transpl Immunol, 2021(66):101386.
|
| [16] |
Brahmer JR, Drake CG, WollnerⅠ, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates[J]. J Clin Oncol, 2010, 28(19):3167-3175.
|
| [17] |
Grigg C, Rizvi NA. PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?[J]. J Immunother Cancer, 2016(4):48.
|
| [18] |
Shi GM, Wang J, Huang XW, et al. Graft programmed deathligand 1 expression as a marker for transplant rejection following anti-programmed death 1 immunotherapy for recurrent liver tumors[J]. Liver Transpl, 2021, 27(3):444-449.
|
| [19] |
Teng MWL, Ngiow SF, Ribas A, et al. Classifying cancers based on T-cell infiltration and PD-L1[J]. Cancer Res, 2015, 75(11):2139-2145.
|
| [20] |
Yi M, Jiao D, Xu H, et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors[J]. Mol Cancer, 2018, 17(1):129.
|
| [21] |
Amos SM, Duong CPM, Westwood JA, et al. Autoimmunity associated with immunotherapy of cancer[J]. Blood, 2011, 118(3):499-509.
|
| [22] |
Barnett R, Barta VS, Jhaveri KD. Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab[J]. N Engl J Med, 2017, 376(2):191-192.
|
| [23] |
Esfahani K, Al-Aubodah TA, Thebault P, et al. Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation[J]. Nat Commun, 2019, 10(1):4712.
|
| [24] |
李照, 朱继业. 免疫治疗时代下的肝癌肝移植[J]. 临床肝胆病杂志, 2021, 37(2):249-252.
|
| [25] |
王俊旗,徐锋.程序性死亡受体1及其配体PD-L1、细胞毒性T淋巴细胞相关抗原4抑制剂在晚期肝癌治疗中的进展[J/CD].中华普通外科学文献（电子版）, 2021, 15(4):304-308.
|
| [26] |
Dai H, Tong C, Shi DW, et al. Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase Ⅱ trial [J]. Oncoimmunology, 2020, 9(1):1846926.
|